| pubmed-article:4059587 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0086045 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0376180 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0068377 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0232552 | lld:lifeskim |
| pubmed-article:4059587 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:4059587 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:4059587 | pubmed:dateCreated | 1985-12-11 | lld:pubmed |
| pubmed-article:4059587 | pubmed:abstractText | We evaluated whether nalmefene, an orally administered opiate-receptor antagonist, would inhibit gastric acid secretion in response to a meal in healthy humans. On separate days either 50 mg nalmefene or a placebo tablet was administered by mouth 90 min before a blenderized steak meal was infused into the stomach through a nasogastric tube. Compared to placebo, nalmefene inhibited meal-stimulated acid secretion in each of 6 subjects studied (P less than 0.05). During the second and third hours after the meal, nalmefene inhibited mean acid secretion by 16%. Nalmefene also resulted in significantly higher meal-stimulated serum gastrin concentrations than placebo (P less than 0.05) even though intragastric pH was kept constant at 5.0 in both experiments. These studies indicate that an orally administered opiate-receptor antagonist can inhibit gastric acid secretion in response to a meal in humans, yet increase meal-stimulated serum gastrin concentrations. | lld:pubmed |
| pubmed-article:4059587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:language | eng | lld:pubmed |
| pubmed-article:4059587 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:4059587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4059587 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:4059587 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:4059587 | pubmed:issn | 0167-0115 | lld:pubmed |
| pubmed-article:4059587 | pubmed:author | pubmed-author:WalshJ HJH | lld:pubmed |
| pubmed-article:4059587 | pubmed:author | pubmed-author:FeldmanMM | lld:pubmed |
| pubmed-article:4059587 | pubmed:author | pubmed-author:MooreLL | lld:pubmed |
| pubmed-article:4059587 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:4059587 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:4059587 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:4059587 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:4059587 | pubmed:pagination | 245-50 | lld:pubmed |
| pubmed-article:4059587 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:meshHeading | pubmed-meshheading:4059587-... | lld:pubmed |
| pubmed-article:4059587 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:4059587 | pubmed:articleTitle | Effect of oral nalmefene, an opiate-receptor antagonist, on meal-stimulated gastric acid secretion and serum gastrin concentration in man. | lld:pubmed |
| pubmed-article:4059587 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:4059587 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:4059587 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:4059587 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:4059587 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:4059587 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
